A. 國科會計畫 (Principal Investigator)
Establishing the Clinical Utility of Pathway Enrichment Analysis and Polygenic Risk Score to Predict Individual Neurocognitive Performance and Treatment Outcomes Using Bipolar Disorder as an Example (NSTC 111-2628-B-006-010-MY3)
Development of systems and precision medicine – take mood disorder as an example (MOST 108-2320-B-006 -047-MY3)
Pharmacogenomics on the potential modulators of AED and multivitamins supplement - a pilot trial to syndicate studies in silico with epileptic patients and in vivo with zebrafish exemplified by vitamin B6 (MOST 106-2320-B-006-053, MOST 107-2320-B-006-017, MOST 108-2320-B-006-005)
Exploration of inflammation and genetic variants interactions in the treatment outcome of bipolar disorder (MOST 107-2320-B-006 -071)
Clinical predictors and treatment of mood stabilizer-induced metabolic abnormalities in bipolar disorder (MOST 105-2320-B-006-014, MOST 106-2320-B-006-040-)
Integration of Pharmacogenomic and Pharmacometabolomic Approaches: Mood Stabilizer-induced Metabolic Abnormalities in Bipolar Disorder (MOST 104-2320-B-006-024)
A genome-wide association study of antidepressant response and insulin resistance in major depressive disorder (NSC 103-2320-B-006-004, MOST 103-2320-B-006-013)
B. 國科會計畫 (Co-Investigator)
探討瓜氨酸化轉譯後修飾之蛋白質在神經膠質母細胞瘤生成和惡化的角色 (NSTC 113-2320-B-037-025, NSTC 114-2320-B-037-009)
探討尿液miRNA在台灣尿路上皮癌病人預後與治療的角色 (NSTC 114-2314-B-384-001-)
丙戊酸引起副作用之危險因子探討及建構預測模型 (NSTC 114-2320-B-075B-002-)
Investigating the Mechanism of Selective Histone Deacetylase Inhibitor-Mediated Cell Death and Potential Therapeutic Targets in Patient-Derived Glioblastoma—Focusing on Pak6 (MOST 111-2314-B-309-001)
Investigating the Mechanism of Selective Histone Deacetylase Inhibitor-Mediated Cell Death and Potential Therapeutic Targets in Patient-Derived Glioblastoma (MOST 110-2314-B-309-001)
The Balance of Excitatory and Inhibitory Neurotransmission in Early Psychosis: from Early Experience to Social Cognition (MOST 110-2314-B-006-060-MY3)
Neural Correlates of Social Cognition Deficits in Bipolar Disorder: Focus on Inflammation and Psychotic Experience (MOST 110-2314-B-006-061-MY3)
Investigating the Mechanism and Role of Nuclear Kit-Mediated Tmod3 and Potential Therapeutic Target in Tki-Resistant Gastrointestinal Stromal Tumor (MOST 109-2314-B-006-080-)
Neurofunctional and Neurochemical Correlates of Social Cognition in Bipolar Disorder (MOST 107-2628-B-006 -005, MOST 109-2628-B-006-004-)
Molecular mechanisms underlying the interaction between metabolic disorders and depression: the role of oxytocin (MOST 106-2320-B-006-052, MOST 107-2320-B-006-016, MOST 108-2320-B-006 -004)
The role of chronic social stress in the comorbidity of mood disorders and metabolic syndrome (MOST 104-2321-B-006-031, MOST 105-2321-B-006-020 -)
Investigating the Role of Nuclear KIT-Regulated Gene Expression in the Tumorigenesis and Therapeutic Target in Gastrointestinal Stromal Tumor (MOST104-2321-B400-019-MY3)
Functional connectivity and associated neuropeptides variations in drug free patients with obsessive-compulsive disorder-- treatment efficacy comparison between serotonin reuptake inhibitor and repetitive transcranial magnetic stimulation (rTMS) (MOST 104-2314-B-006 -054 -MY3)
C. 教育部計畫 (Principal Investigator)
轉譯藥物基因體學之教學：以實作訓練工作坊強化問題導向學習與實證醫學之學習成效 (MOE-114-TPRMN-0005-015Y1) (PI)
生物製劑的革命：以雙鑽石模型結合問題導向學習重構生物製劑與藥品劑型設計教學 (MOE-113-TPRMN-0005-003Y1) (PI)
以問題導向學習結合實證醫學重構藥物基因體學教學 (PI)
D. 衛生福利部食品藥物管理署
114年度-強化藥品臨床試驗監督管理及精進GCP查核制度計畫 (協同主持人)
113年度-強化藥品臨床試驗監督管理及精進GCP查核制度計畫 (協同主持人)
112年度-強化藥品臨床試驗監督管理及精進GCP查核制度計畫 (協同主持人)
E. 其他產學合作案
營養補充品於抗憂鬱劑治療之憂鬱症病患的可能效應 (coPI)